drugset / Trial / NCT06922110
An Open-Label Study of Azetukalner in Major Depressive Disorder
NaSingle-groupOpen-labelTreatment
Summary
X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).
Timeline
- Start
- 2025-03-18
- Primary completion
- 2027-01
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azetukalner | Small molecule | 20 mg | Oral |